HUP0303530A2 - Szubsztituált pirrolokinolinok és piridokinolinok mint szerotonin-agonisták és -antagonisták és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Szubsztituált pirrolokinolinok és piridokinolinok mint szerotonin-agonisták és -antagonisták és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303530A2
HUP0303530A2 HU0303530A HUP0303530A HUP0303530A2 HU P0303530 A2 HUP0303530 A2 HU P0303530A2 HU 0303530 A HU0303530 A HU 0303530A HU P0303530 A HUP0303530 A HU P0303530A HU P0303530 A2 HUP0303530 A2 HU P0303530A2
Authority
HU
Hungary
Prior art keywords
antagonists
serotonin agonists
pyridoquinolines
pyrroloquinolines
stituted
Prior art date
Application number
HU0303530A
Other languages
English (en)
Inventor
Joseph Cacciola
Wenting Chen
John M. Fevig
Taekyu Lee
Ian S. Mitchell
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0303530A2 publication Critical patent/HUP0303530A2/hu
Publication of HUP0303530A3 publication Critical patent/HUP0303530A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgyát az általános képletű új vegyületek - ahol R1, R6a,R6b, R7, R8, R9 és X különböző, adott esetben szubsztituált csoportok;b egyes kötés, ahol a hozzátartozó hidrogénatomok cisz vagy transztérállásúak; m és n 1 vagy 2 - vagy gyógyszerészetileg elfogadhatósóik, továbbá ezeket tartalmazó gyógyszerkészítmények képezik. Atalálmányszerinti új vegyületek szerotonin agonisták vagyantagonisták, és különböző központi idegrendszeri betegségek, példáulelhízás, szorongás, depresszió, pszichózisok, skizofrénia, alvásirendellenességek, szexuális rendellenességek, migrén, fejfájássalkapcsolatos állapotok, szociális fóbiák és a gyomor-bél traktusműködési zavarainak kezelésében vagy megelőzésében alkalmazhatók. Ó
HU0303530A 2000-12-20 2001-12-19 Stituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists and pharmaceutical compositions containing them HUP0303530A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25674500P 2000-12-20 2000-12-20
PCT/US2001/049380 WO2002059124A2 (en) 2000-12-20 2001-12-19 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists

Publications (2)

Publication Number Publication Date
HUP0303530A2 true HUP0303530A2 (hu) 2004-01-28
HUP0303530A3 HUP0303530A3 (en) 2012-10-29

Family

ID=22973430

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303530A HUP0303530A3 (en) 2000-12-20 2001-12-19 Stituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists and pharmaceutical compositions containing them

Country Status (23)

Country Link
US (1) US6777406B2 (hu)
EP (1) EP1399445B9 (hu)
JP (1) JP4386639B2 (hu)
KR (1) KR20030070590A (hu)
AT (1) ATE438646T1 (hu)
AU (1) AU2002246726B2 (hu)
BG (1) BG107863A (hu)
BR (1) BR0116348A (hu)
CA (1) CA2432181C (hu)
CZ (1) CZ20031707A3 (hu)
DE (1) DE60139511D1 (hu)
EE (1) EE200300303A (hu)
ES (1) ES2329553T4 (hu)
HU (1) HUP0303530A3 (hu)
IL (1) IL156261A0 (hu)
IS (1) IS6851A (hu)
MX (1) MXPA03005355A (hu)
NO (1) NO20032798L (hu)
PL (1) PL366627A1 (hu)
RU (1) RU2003121306A (hu)
SK (1) SK7032003A3 (hu)
WO (1) WO2002059124A2 (hu)
ZA (1) ZA200304304B (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
EP2595988B1 (en) * 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
CN104169268A (zh) 2012-01-18 2014-11-26 扎夫根股份有限公司 三环砜化合物及其制备和使用方法
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
KR20150079952A (ko) 2012-11-05 2015-07-08 자프겐 인크. 트리시클릭 화합물 및 그의 제조 및 사용 방법
KR20150079951A (ko) 2012-11-05 2015-07-08 자프겐 인크. 간 질환의 치료 방법
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9822117B2 (en) * 2013-03-04 2017-11-21 Daya Drug Discoveries, Inc. Pyridoindolobenz[b,d]azepine derivatives and uses thereof
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN109897039B (zh) * 2019-03-13 2021-03-30 中国科学院化学研究所 一种制备吡咯并[3,2,1-ij]喹啉酮化合物的方法
AU2022258453A1 (en) * 2021-04-13 2023-10-19 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
HUT61548A (en) * 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds

Also Published As

Publication number Publication date
BG107863A (en) 2004-06-30
CA2432181C (en) 2009-11-17
IL156261A0 (en) 2004-01-04
HUP0303530A3 (en) 2012-10-29
WO2002059124A2 (en) 2002-08-01
CA2432181A1 (en) 2002-08-01
EP1399445B1 (en) 2009-08-05
EP1399445A2 (en) 2004-03-24
JP4386639B2 (ja) 2009-12-16
IS6851A (is) 2003-06-18
BR0116348A (pt) 2004-11-23
CZ20031707A3 (cs) 2003-11-12
EE200300303A (et) 2003-12-15
KR20030070590A (ko) 2003-08-30
MXPA03005355A (es) 2004-05-27
ZA200304304B (en) 2004-09-02
JP2004528290A (ja) 2004-09-16
EP1399445B9 (en) 2010-07-21
NO20032798L (no) 2003-08-19
PL366627A1 (en) 2005-02-07
US6777406B2 (en) 2004-08-17
ES2329553T4 (es) 2010-12-07
WO2002059124A3 (en) 2004-01-08
ES2329553T3 (es) 2009-11-27
US20040092502A1 (en) 2004-05-13
AU2002246726B2 (en) 2007-03-01
RU2003121306A (ru) 2005-03-10
NO20032798D0 (no) 2003-06-19
SK7032003A3 (en) 2004-04-06
DE60139511D1 (de) 2009-09-17
ATE438646T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
HUP0303530A2 (hu) Szubsztituált pirrolokinolinok és piridokinolinok mint szerotonin-agonisták és -antagonisták és ezeket tartalmazó gyógyszerkészítmények
BG107865A (en) Substituted pyridoindoles as serotonin agonists and antagonists
MXPA01012914A (es) Gama-carbolinas fundidas de heterociclo substituido.
IS7891A (is) Skiptitengd þrísýklísk gamma-karbólín sem serótónín viðtaka gerandefni og mótverkunarefni
BR9506924A (pt) Composição farmacêutica sublingual ou bucal e utilização do trans-5-cloro-2-metil-2,3,3a, 12b-tetraidro-1h-dibenz(2,3:6,7) oxepino(4,5-c)pirrol
PT1716152E (pt) Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais
SE0104341D0 (sv) New use
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0204010A2 (hu) Új szertralin-hidroklorid polimorfok, eljárás az előállításukra, az új polimorfokat tartalmazó gyógyszerkészítmények és alkalmazásuk
DE602004006869D1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
HUP0402515A2 (hu) Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
ATE318819T1 (de) Pyrazinochinoxalin-derivate als serotonin- agonisten und -antagonisten
HUP0303316A2 (hu) Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
SE9803158D0 (sv) A new composition
HUP0201720A2 (hu) Szorongás és depresszió kezelésére szolgáló kombinált készítmények és alkalmazásuk
HUP0300032A2 (en) Use of compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoreceptor for preparation of pharmaceutical composition

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished